Elite Pharmaceuticals, Inc. ("Elite" or the "Company") /quotes/zigman/218918 ELTP -2.13% today announced that it has entered into an agreement to develop for a private Hong Kong-based company (the "Customer") a branded prescription pharmaceutical product. Under the terms of the agreement, the Customer will provide the formulation for the product and Elite will undertake a developmental program for the product. The Customer shall be responsible for the filing of the New Drug Application ("NDA") for the finished product and the NDA will be filed under the Customer's name. Upon approval of the NDA, Elite will retain certain rights to manufacture the product. The Customer will be responsible for the marketing and sales of the final product. The Customer will pay Elite milestone payments for the development work.
Showing posts with label Elite Pharmaceuticals. Show all posts
Showing posts with label Elite Pharmaceuticals. Show all posts
Elite Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year Ending March 31st, 2011 Investor Conference Call on Thursday, June 30, 2011
Elite Pharmaceuticals, Inc. , a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and controlled release product formulations and generics with high barriers to entry, announced today the Company will host a conference call on Thursday, June 30, 2011 at 4:30 PM EDT to review fourth quarter and year-end 2011 results of operations and provide an update on recent business developments Company executives will also conduct a question and answer session following their remarks.
To access the conference call:
Domestic callers: (800) 346-7359 International callers: (973) 528-0008 Conference Entry Code: 98840
A digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until July 22, 2010 by dialing:
Domestic callers: (800) 332-6854 International callers: (973) 528-0005 Conference entry code: 98840
Subscribe to:
Posts (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac... -
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma... -
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th... -
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after... -
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y... -
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
-
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ...